ID: ALA5266032

Max Phase: Preclinical

Molecular Formula: C19H15N3O2

Molecular Weight: 317.35

Representations

Canonical SMILES:  COc1cc(Oc2ccnc3ccccc23)cc(-n2cccn2)c1

Standard InChI:  InChI=1S/C19H15N3O2/c1-23-15-11-14(22-10-4-8-21-22)12-16(13-15)24-19-7-9-20-18-6-3-2-5-17(18)19/h2-13H,1H3

Standard InChI Key:  GROZLUGXTULRLN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 317.35

Molecular Weight (Monoisotopic): 317.1164

AlogP: 4.22

#Rotatable Bonds: 4

Polar Surface Area: 49.17

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.30

CX LogP: 3.56

CX LogD: 3.56

Aromatic Rings: 4

Heavy Atoms: 24

QED Weighted: 0.57

Np Likeness Score: -1.37

References

1. Lv G, Shi Q, Zhang T, Li J, Long Y, Zhang W, Choudhry N, Yang K, Li H, Kalashova J, Yang C, Zhou X, Reddy MC, Anantoju KK, Zhang S, Zhang J, Allen TD, Liu H, Nimishetti N, Yang D..  (2023)  Integrating a phenotypic screening with a structural simplification strategy to identify 4-phenoxy-quinoline derivatives to potently disrupt the mitotic localization of Aurora kinase B.,  80  [PMID:36696874] [10.1016/j.bmc.2023.117173]

Source

Source(1):

• Scientific Literature